Ca2+-induced contraction of cat esophageal circular smooth muscle cells.
ACh-induced contraction of esophageal circular muscle (ESO) depends on Ca2+ influx and activation of protein kinase Cepsilon (PKCepsilon). PKCepsilon, however, is known to be Ca2+ independent. To determine where Ca2+ is needed in this PKCepsilon-mediated contractile pathway, we examined successive steps in Ca2+-induced contraction of ESO muscle cells permeabilized by saponin. Ca2+ (0.2-1.0 microM) produced a concentration-dependent contraction that was antagonized by antibodies against PKCepsilon (but not by PKCbetaII or PKCgamma antibodies), by a calmodulin inhibitor, by MLCK inhibitors, or by GDPbetas. Addition of 1 microM Ca2+ to permeable cells caused myosin light chain (MLC) phosphorylation, which was inhibited by the PKC inhibitor chelerythrine, by D609 [phosphatidylcholine-specific phospholipase C inhibitor], and by propranolol (phosphatidic acid phosphohydrolase inhibitor). Ca2+-induced contraction and diacylglycerol (DAG) production were reduced by D609 and by propranolol, alone or in combination. In addition, contraction was reduced by AACOCF(3) (cytosolic phospholipase A(2) inhibitor). These data suggest that Ca2+ may directly activate phospholipases, producing DAG and arachidonic acid (AA), and PKCepsilon, which may indirectly cause phosphorylation of MLC. In addition, direct G protein activation by GTPgammaS augmented Ca2+-induced contraction and caused dose-dependent production of DAG, which was antagonized by D609 and propranolol. We conclude that agonist (ACh)-induced contraction may be mediated by activation of phospholipase through two distinct mechanisms (increased intracellular Ca2+ and G protein activation), producing DAG and AA, and activating PKCepsilon-dependent mechanisms to cause contraction.
Cao
W
W
Department of Medicine, Rhode Island Hospital and Brown Medical School, 593 Eddy St., Providence, RI 02903, USA.
Chen
Q
Q
Sohn
U D
UD
Kim
N
N
Kirber
M T
MT
Harnett
K M
KM
Behar
J
J
Biancani
P
P
D000319:Adrenergic beta-Antagonists / Q000494:pharmacology; D000470:Alkaloids; D000818:Animals; D000906:Antibodies / Q000494:pharmacology; D001381:Azepines / Q000494:pharmacology; D053119:Benzophenanthridines; D001952:Bridged-Ring Compounds / Q000494:pharmacology; D002118:Calcium / Q000378:metabolism / Q000494:pharmacology*; D020013:Calcium Signaling / Q000187:drug effects / Q000502:physiology*; D002415:Cats; D004305:Dose-Response Relationship, Drug; D004791:Enzyme Inhibitors / Q000494:pharmacology; D004947:Esophagus / Q000502:physiology*; D004963:Estrenes / Q000494:pharmacology; D005260:Female; D016244:Guanosine 5'-O-(3-Thiotriphosphate) / Q000494:pharmacology; D007527:Isoenzymes / Q000037:antagonists & inhibitors / Q000276:immunology / Q000378:metabolism; D008297:Male; D009119:Muscle Contraction / Q000187:drug effects / Q000502:physiology*; D009130:Muscle, Smooth / Q000502:physiology*; D018994:Myosin Light Chains / Q000037:antagonists & inhibitors / Q000378:metabolism; D009281:Naphthalenes / Q000494:pharmacology; D009636:Norbornanes; D010617:Phenanthridines / Q000494:pharmacology; D010726:Phosphodiesterase Inhibitors / Q000494:pharmacology; D010739:Phospholipase D / Q000037:antagonists & inhibitors / Q000378:metabolism; D010766:Phosphorylation; D011433:Propranolol / Q000494:pharmacology; D011493:Protein Kinase C / Q000037:antagonists & inhibitors / Q000276:immunology / Q000378:metabolism; D051744:Protein Kinase C-epsilon; D011760:Pyrrolidinones / Q000494:pharmacology; D011794:Quercetin / Q000494:pharmacology; D015290:Second Messenger Systems / Q000502:physiology; D013859:Thiocarbamates; D013871:Thiones / Q000494:pharmacology; D010738:Type C Phospholipases / Q000037:antagonists & inhibitors / Q000378:metabolism
D000319:Adrenergic beta-Antagonists; D000470:Alkaloids; D000906:Antibodies; D001381:Azepines; D053119:Benzophenanthridines; D001952:Bridged-Ring Compounds; D004791:Enzyme Inhibitors; D004963:Estrenes; D007527:Isoenzymes; D018994:Myosin Light Chains; D009281:Naphthalenes; D009636:Norbornanes; D010617:Phenanthridines; D010726:Phosphodiesterase Inhibitors; D011760:Pyrrolidinones; D013859:Thiocarbamates; D013871:Thiones; C070571:ML 7; C060229:1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione; D016244:Guanosine 5'-O-(3-Thiotriphosphate); C046498:tricyclodecane-9-yl-xanthogenate; D011794:Quercetin; D011433:Propranolol; C016299:chelerythrine; D011493:Protein Kinase C; D051744:Protein Kinase C-epsilon; D010738:Type C Phospholipases; D010739:Phospholipase D; D002118:Calcium